Boehringer Ingelheim receives FDA Breakthrough Therapy designation for survodutide, a dual glucagon/GLP-1 receptor agonist, for treating non-cirrhotic MASH with moderate or advanced fibrosis. Two Phase III studies, LIVERAGE and LIVERAGE-Cirrhosis, are initiated to assess survodutide's efficacy in MASH patients with fibrosis and cirrhosis, respectively.